Manuel Wallbach
YOU?
Author Swipe
View article: Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF
Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF Open
Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenon…
View article: Urinary Dickkopf‐3 as a Potential Marker for Estimated Glomerular Filtration Rate Decline in Patients With Heart Failure
Urinary Dickkopf‐3 as a Potential Marker for Estimated Glomerular Filtration Rate Decline in Patients With Heart Failure Open
Background Patients with chronic heart failure (HF) show an increased risk for the occurrence of chronic kidney disease and cardiorenal syndrome. Urinary Dickkopf‐3 (uDKK3), a stress‐induced, tubular profibrotic glycoprotein, may be elevat…
View article: Effects of SGLT2 inhibitors on parameters of renal venous congestion in intrarenal Doppler ultrasonography
Effects of SGLT2 inhibitors on parameters of renal venous congestion in intrarenal Doppler ultrasonography Open
Background Cardiorenal syndrome is a common condition in clinical practice in which renal venous congestion (VC) plays an important role. Intrarenal Doppler ultrasound (IRD) is a non-invasive method to assess and quantify renal VC. The cur…
View article: Effects of baroreflex activation therapy on cardiac function and morphology
Effects of baroreflex activation therapy on cardiac function and morphology Open
Aims Arterial hypertension (aHTN) plays a fundamental role in the pathogenesis and prognosis of heart failure with preserved ejection fraction (HFpEF). The risk of heart failure increases with therapy‐resistant arterial hypertension (trHTN…
Increased Expression of Proinflammatory Genes in Peripheral Blood Cells Is Associated with Cardiac Cachexia in Patients with Heart Failure with Reduced Ejection Fraction Open
Background: Cardiac cachexia (CC) in chronic heart failure with reduced ejection fraction (HFrEF) is characterized by catabolism and inflammation predicting poor prognosis. Levels of responsible transcription factors like signal transducer…
Intrarenal Doppler ultrasonography in patients with HFrEF and acute decompensated heart failure undergoing recompensation Open
Objectives Renal venous congestion due to backward heart failure leads to disturbance of renal function in acute decompensated heart failure (ADHF). Whether decongestion strategies have an impact on renal venous congestion is unknown. Obje…
View article: Urinary Dickkopf-3 (DKK3) Is Associated with Greater eGFR Loss in Patients with Resistant Hypertension
Urinary Dickkopf-3 (DKK3) Is Associated with Greater eGFR Loss in Patients with Resistant Hypertension Open
Patients with resistant hypertension (HTN) demonstrate an increased risk of chronic kidney disease and progression to end-stage renal disease; however, the individual course of progression is hard to predict. Assessing the stress-induced, …
Effect of baroreflex activation therapy on dipping pattern in patients with resistant hypertension Open
A relevant number of patients with resistant hypertension do not achieve blood pressure (BP) dipping during nighttime. This inadequate nocturnal BP reduction is associated with elevated cardiovascular risks. The aim of this study was to ev…
Impact of Elevated LDH on Cystatin C-Based Glomerular Filtration Rate Estimates in Patients with Cancer Open
Background: The determination of renal function is crucial for the clinical management of patients with cancer. The glomerular filtration rate (GFR) serves as a key parameter, estimated by creatinine clearance determination in 24-h collect…
View article: Impact of medication adherence on the efficacy of Baroreflex activation therapy
Impact of medication adherence on the efficacy of Baroreflex activation therapy Open
Therapy adherence significantly determines the success of antihypertensive therapy, especially in patients with resistant hypertension. Our study investigates the impact of drug adherence on the efficacy of Baroreflex‐activation‐therapy (B…
Toxicology, including therapeutic drug monitoring Open
BACKGROUND-AIMPharmacogenetics is a discipline oriented to the study of the genetic basis of interindividual differences in the response to drugs, both at the level of efficacy and safety.One of the most widely used applications of Pharmac…
The Rapid Atrial Swirl Sign for Ultrasound-Guided Tip Positioning of Retrograde-Tunneled Hemodialysis Catheters: A Cross-Sectional Study from a Single Center Open
Background: Chronic kidney disease (CKD) is a common medical problem in patients worldwide, with an increasing prevalence of patients with end-stage kidney disease (ESKD) requiring renal replacement therapy (RRT). In patients requiring RRT…
View article: Cystatin C predicts renal function impairment after partial or radical tumor nephrectomy
Cystatin C predicts renal function impairment after partial or radical tumor nephrectomy Open
Purpose To test the value of preoperative and postoperative cystatin C (CysC) as a predictor on kidney function after partial (PN) or radical nephrectomy (RN) in renal cell carcinoma (RCC) patients with normal preoperative renal function. …
Eligibility for Baroreflex Activation Therapy and medication adherence in patients with apparently resistant hypertension Open
Uncontrolled hypertension is a main risk factor for cardiovascular morbidity. Baroreflex activation therapy (BAT) is an effective therapy option addressing true resistant hypertension. We evaluated patients’ eligibility for BAT in a staged…
Cytokine adsorption therapy in lymphoma-associated hemophagocytic lymphohistiocytosis and allogeneic stem cell transplantation Open
Lymphoma-associated Hemophagocytic lymphohistiocytosis (HLH) represents a severe complication of disease progression, mediated through cytokine release from the lymphoma cells. Cytokine adsorption may contribute as a supportive treatment t…
Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension Open
(1) Background: Arterial hypertension (HTN) is one of the most relevant cardiovascular risk factors. Nowadays multiple pharmaceutical treatment options exist with novel interventional methods (e.g., baroreflex activation therapy (BAT)) as …
Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis Open
Multiple sclerosis (MS) is an inflammatory disease mainly affecting the central nervous system. In MS, abnormal immune mechanisms induce acute inflammation, demyelination, axonal loss, and the formation of central nervous system plaques. T…
Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients Open
Diabetic nephropathy (DN) is the main reason for end-stage renal disease. Microalbuminuria as the non-invasive available diagnosis marker lacks specificity and gives high false positive rates. To identify and validate biomarkers for DN, we…
Efficacy of Electrical Baroreflex Activation Is Independent of Peripheral Chemoreceptor Modulation Open
Arterial baroreflex activation through electrical carotid sinus stimulation has been developed for the treatment of resistant hypertension. Previous studies suggested that the peripheral chemoreflex is tonically active in hypertensive pati…
Direct assessment of adherence and drug interactions in patients with hypertensive crisis—A cross‐sectional study in the Emergency Department Open
Though drug adherence is supposed to be low in hypertensive crisis (HTN‐C), there are no data available from direct adherence assessments. The aim of the present study was to evaluate adherence to prescribed antihypertensives and potential…
Editorial Comment from Dr Schmid and Dr Wallbach to Acute kidney injury and intermediate‐term renal function after clampless partial nephrectomy Open
None declared.
Kidney protective effects of baroreflex activation therapy in patients with resistant hypertension Open
Baroreflex activation therapy (BAT) is approved for the treatment of resistant hypertension. In addition to blood pressure (BP) reduction, pilot studies suggested several organoprotective effects of BAT. Thirty‐two patients with resistant …
View article: Safety profile of baroreflex activation therapy (NEO) in patients with resistant hypertension
Safety profile of baroreflex activation therapy (NEO) in patients with resistant hypertension Open
Though there are common side effects, Barostim neo significantly lowers blood pressure in resistant hypertension and provides an adequate safety profile. Regular patient visits are necessary to register side effects.
Difference between renal and splenic resistive index as a novel criterion in Doppler evaluation of renal artery stenosis Open
Detection of renal artery stenosis ( RAS ) using Doppler is difficult to evaluate, particularly under conditions such as bilateral RAS or difficultly accessible renal arteries ( RA ). The objective of the present study was to assess the ut…
Baroreceptors in the carotid and hypertension—systematic review and meta-analysis of the effects of baroreflex activation therapy on blood pressure Open
Activation of baroreceptors in the carotid modulates the autonomic nervous system. Baroreflex activation therapy (BAT), which activates baroreceptors in the carotid, has become available in the treatment of resistant hypertension. Besides …